TY - JOUR
T1 - ALSUntangled #79
T2 - alpha-lipoic acid
AU - Giacobbe, Alaina
AU - Hiana, James
AU - Wang, Olivia
AU - Benatar, Michael
AU - Wicks, Paul
AU - Mascias Cadavid, Javier
AU - Jhooty, Sartaj
AU - McDermott, Christopher
AU - Pattee, Gary
AU - Bertorini, Tulio
AU - Heiman-Patterson, Terry
AU - Ratner, Dylan
AU - Barkhaus, Paul
AU - Carter, Gregory
AU - Jackson, Carlayne
AU - Denson, Keelie
AU - Brown, Andrew
AU - Armon, Carmel
AU - Sun, Yuyao
AU - Nguyen, Andre
AU - Bedlack, Richard
AU - Li, Xiaoyan
N1 - Publisher Copyright:
© 2025 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.
PY - 2026
Y1 - 2026
N2 - Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It serves as an essential cofactor for enzymatic reactions in mitochondrial energy production, is a potent antioxidant and has anti-inflammatory effects, which are plausible mechanisms in slowing ALS progression. In ALS preclinical studies, ALA slowed motor function decline and improved survival. There were self-reported cases of improved muscle strength in ALS patients when ALA was taken with numerous additional supplements, making it difficult to discern its efficacy. One small, 6-month open-label study showed improved quality of life, fatigue, and mood after participants took it with B vitamins and amino acids for the first 3 months. So far, no clinical trials have been published in people living with amyotrophic lateral sclerosis (PALS). Given the insufficient clinical data, we cannot endorse ALA and will support more research on its efficacy in slowing ALS progression.
AB - Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It serves as an essential cofactor for enzymatic reactions in mitochondrial energy production, is a potent antioxidant and has anti-inflammatory effects, which are plausible mechanisms in slowing ALS progression. In ALS preclinical studies, ALA slowed motor function decline and improved survival. There were self-reported cases of improved muscle strength in ALS patients when ALA was taken with numerous additional supplements, making it difficult to discern its efficacy. One small, 6-month open-label study showed improved quality of life, fatigue, and mood after participants took it with B vitamins and amino acids for the first 3 months. So far, no clinical trials have been published in people living with amyotrophic lateral sclerosis (PALS). Given the insufficient clinical data, we cannot endorse ALA and will support more research on its efficacy in slowing ALS progression.
KW - ALS
KW - alpha lipoic acid
KW - antiinflammation
KW - antioxidant
KW - oxidative stress
UR - https://www.scopus.com/pages/publications/105005840079
U2 - 10.1080/21678421.2025.2507166
DO - 10.1080/21678421.2025.2507166
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 40411245
AN - SCOPUS:105005840079
SN - 2167-8421
VL - 27
SP - 233
EP - 237
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 1-2
ER -